Dr. Izidore Lossos, MD

Dr. Lossos practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Lossos' NPI, 1588628093, was assigned on April 13, 2006. Dr. Lossos graduated from The Hebrew University of Jerusalem Hadassah Medical School in 1987. Dr. Lossos holds Florida license MFC1489.

Dr. Lossos' primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Lossos' primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Lossos is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lossos practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lossos' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Lossos' licenses on file in 2 states: Florida and Oregon.

Dmand AI lists chronic leukemia and lymphoma among the conditions Dr. Lossos treats.

CMS data shows 360 Medicare services from Dr. Lossos across 4 procedure codes in 2024, for 137 Medicare patients. Medicare paid $30,306 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 137 Medicare patients who saw Dr. Lossos in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 21% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lossos' median patient age at 71, with 42% women.

In 2024, Dr. Lossos wrote 254 Medicare Part D claims for 38 patients. 54% of them were for generic drugs. CMS names the drug for 162 of them, across 9 drugs with 11 or more claims each, at $1,184,952 in total drug cost. In 2023, CMS named 150 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Lossos for performance year 2024, reported as part of a group. Dr. Lossos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lossos as offering telehealth.

Dmand AI links 304 papers to Dr. Lossos, published from 2002 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols and Lymphoma, B-Cell, Marginal Zone. Dr. Lossos has published most often in Leuk Lymphoma. Dr. Lossos' most frequent co-authors are Juan Pablo Alderuccio, MD, Yasodha Natkunam, MD, PhD and Thomas M. Habermann, MD.

Dmand AI links Dr. Lossos to 7 clinical trials, 5 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin and Lymphoma, Large B-Cell, Diffuse. University of Miami sponsors the most, 5. Open Payments lists research payments to Dr. Lossos that name 1 trial.

CMS Open Payments shows 106 general payments to Dr. Lossos from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Swedish Orphan Biovitrum AB paid the most, $14,800. It also lists 15 research payments totaling $11,877 from 2016 to 2025, naming 1 clinical trial.

Dmand AI lists 5 awards for Dr. Lossos, most recently America's Top Doctors in 2014.

Dr. Lossos graduated from The Hebrew University of Jerusalem Hadassah Medical School in 1987.

Dr. Lossos is in network with 10 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.